Skip to content
OpenCapital
Get started

TScan Therapeutics, Inc. TCRX Q4 2025 Annual earnings

Reported March 4, 2026 · Before market open

Revenue$2.6MBeat by $131.5K
EPS-$0.18Beat by $0.09
Revenue estimate$2.4M
EPS estimate-$0.27

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$1.9M
EPS estimate-$0.29

Versus estimates

Revenue

Q1 2026$982.0KMiss by $1.5M
Q4 2025$2.6MBeat by $131.5K
Q3 2025$2.5MBeat by $571.0KQ2 2025$3.1MBeat by $1.2MQ1 2025$2.2MBeat by $1.1MQ4 2024$665.0KMiss by $854.8K

Diluted EPS

Q1 2026-$0.22In line
Q4 2025-$0.18Beat by $0.09
Q3 2025-$0.28Beat by $0.07Q2 2025-$0.28In lineQ1 2025-$0.26Beat by $0.02Q4 2024-$0.29Miss by $0.02

Ask the moment TScan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TScan Therapeutics, Inc. report Q4 2025 earnings?
TScan Therapeutics, Inc. (TCRX) reported Q4 2025 earnings on March 4, 2026 before market open.
What were TScan Therapeutics, Inc.'s Q4 2025 revenue and EPS?
TScan Therapeutics, Inc. reported revenue of $2.6M and eps of $-0.18 for Q4 2025.
Did TScan Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $2.4M by $131.5K. EPS beat the consensus estimate of $-0.27 by $0.09.
How did TScan Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 286.0% from $665.0K a year earlier and eps grew 37.9% from $-0.29.
Where can I find TScan Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-089871) and the 10-K periodic report (0001193125-26-089884) directly on SEC EDGAR. The filing index links above go to sec.gov.